Fineline Cube

Follow:
14499 Articles
4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials
CompanyDrug

4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials

Pfizer Licenses 3SBio's Bispecific Antibody SSGJ-707 in Global Deal Excluding China
CompanyDeals

Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China

Bayer's Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment
CompanyDrug

Bayer’s Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment

Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike
Company

Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike

CSPC Pharmaceutical's CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC
CompanyDrug

CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
CompanyDrug

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer

Terumo Corporation Acquires WuXi Biologics' Germany Plant for EUR 150 Million
CompanyDeals

Terumo Corporation Acquires WuXi Biologics’ Germany Plant for EUR 150 Million

Grand Pharma's Chengdu RDC Megafactory Secures Class A Radiation Safety License
Company

Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License

Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma
CompanyDrug

Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma

Shanghai MicroPort's Minos Stent Graft Secures Egyptian Marketing Approval
CompanyMedical Device

Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval

Sino Biopharmaceutical's QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain
CompanyDrug

Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain

CompanyDeals

Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases